Presented at #ATS2023: In the BOREAS trial, dupilumab resulted in a lower annualized rate of exacerbations than placebo among patients with COPD and an elevated blood eosinophil count. Full trial results: https://t.co/9IWZr3YqsN
ERJ: This study demonstrates that pulmonologists improve their individual diagnostic interpretation of pulmonary function tests when supported by AI-based computer protocols with automated explanations. Such teamwork may become commonplace in the future. https://t.co/3CDL1egHcQ
ERJ: A European multi-stakeholder working group has reached a consensus on Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA). These should inform future clinical trials and enhance comparability of findings. https://t.co/wfuWSnjDJi
ERJ: Diagnostic protocols for the assessment of small airway disease have been advanced to optimise the clinical management of patients with asthma https://t.co/srZNJybvCz
The ICD-11 has adopted three timeframes for dyspnoea: acute, subacute and chronic, the latter despite underlying causes being optimally treated. Breathlessness, a word patients use, is now a synonym for dyspnoea. https://t.co/yDqyykFfD4
ERJ: Asthma patients with small airways dysfunction (SAD) could be identified reasonably well by asking about wheezing at rest and a few patient characteristics, but accuracy to predict SAD increases considerably when using lung function tests https://t.co/8IuYzOXlKs
The recent release of ChatGPT and other artificial intelligence tools have put a spotlight on this developing topic. This thread explores the history of AI in medicine, clinical uses of AI and machine learning, and the use of chatbots. Full article: https://t.co/Euor4SHIt9 1/24
Study finds that hydrocortisone for patients w/severe pneumonia, cuts the risk of death by about half
Read story from @statnews here: https://t.co/4luDNOwNg0
And the study from @NEJM here: https://t.co/lTIjl69V9a
Hydrocortisone in Severe Community-Acquired Pneumonia
➡️ 800 pts
➡️ IV hydrocortisone 200 mg daily for 4 or 8 days or placebo
➡️ D28 mortality: 6.2% vs 11.9% (difference, −5.6%; 95% CI, −9.6 to −1.7; P=0.006)
CCR Journal Watch
https://t.co/Sp06oA6IDG
Asthma diagnosis in adults still remains a challenge with over- and under-diagnosis. Spirometry with reversibility testing is essential. Nitric oxide, peak expiratory flow variability and bronchial challenge testing should also be considered. https://t.co/DrviIWfN9X